GlassScriptPhysician profile
Nedaa Skeik
NPI 1295768554
$453,158.76
in general payments reported to CMS, 2019-2025
17 companies · $40K in 2025
The $40K reported for 2025 was more than what 98% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $130K · 2020: $52K · 2021: $76K · 2022: $49K · 2023: $59K · 2024: $48K · 2025: $40K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $107K · Travel and Lodging: $19K · Honoraria: $14K · Consulting Fee: $4,710 · Food and Beverage: $2,358.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $106,603.31 |
| Travel and Lodging | $18,846.96 |
| Honoraria | $14,040.00 |
| Consulting Fee | $4,710.00 |
| Food and Beverage | $2,357.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $172,981.23 | 2019-2024 | Xarelto |
| Novo Nordisk INC | $80,594.78 | 2021-2025 | Ozempic |
| Astrazeneca Pharmaceuticals LP | $50,893.09 | 2020-2023 | Andexxa, Farxiga |
| Pfizer INC. | $46,010.18 | 2019-2021 | |
| Portola Pharmaceuticals, LLC | $27,417.54 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24,125.57 | 2019-2022 | |
| Boston Scientific Corporation | $19,160.35 | 2019-2022 | |
| Lexicon Pharmaceuticals, INC. | $15,437.73 | 2023-2024 | Inpefa |
| Lilly USA, LLC | $9,322.59 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $3,425.00 | 2019-2021 | |
| Inari Medical, INC. | $1,250.00 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Alexion Pharmaceuticals, INC. | $1,140.00 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $935.73 | 2023 | |
| Medtronic, INC. | $333.92 | 2021 | |
| W. L. Gore & Associates, INC. | $115.75 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $15.30 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nedaa Skeik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.